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doi:10.1016/j.jmii.2011.12.001Background/Purpose: The incidence of Clostridium difficile-associated diarrhea (CDAD) is
increasing worldwide. Spread of an epidemic hypervirulent strain in southern Taiwan was asso-
ciated with poor outcome. This prospective study evaluates the incidence and clinical manifes-
tation of CDAD following a hospital-wide hand hygiene promotion program in a 2,200-bed
teaching hospital in northern Taiwan.
Patients and Methods: From June 1, 2010 to October 31, 2010, a predefined protocol was used
to actively survey CDAD at 11 high-risk units. Stool samples of patients with antibiotic-
associated diarrhea (AAD) were submitted for stool culture and toxin A/B assay using
a combined enzyme immunoassay. CDAD was diagnosed by a positive toxin assay.
Results: The incidence of CDAD was 0.45/1000 patient-days and was highest in medical inten-
sive care units (7.9/1000 patient-days), followed by hemato-oncology wards, and infectious
disease wards. Occurrence of CDAD was associated with 3 stool pus cells per high power field
(pZ 0.018), prior use of metronidazole (pZ 0.029), high usage of beta-lactamase stable peni-
cillins (pZ 0.046), and anaerobe-active antibiotics (pZ 0.029). No attributable mortality was
found. The incidence of CDAD was lower than that previously observed (1.0/1000 patient-days
in 2003, p < 0.001).of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10016,
il.com (Y.-C. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
288 Y.-C. Lee et al.Conclusion: This study showed a lower incidence of CDAD and absence of attributable
mortality. The impact of hand hygiene promotion and other infection control measures on
decreasing incidence of CDAD warrants further elucidation.
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Chronic pancreatitis, n = 1 
Parasite infection, n = 0 
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Enrolled for active microbial 
surveillance Introduction
Clostridium difficile-associated diarrhea (CDAD) contribute
to 20% to 30% of patients with antibiotic-associated
diarrhea (AAD), and more than 90% of those with
antibiotic-associated pseudomembranous colitis.1 CDAD has
progressively increased in United States in the last decade.2
Of even greater concern are the increases in severe or fatal
infection.3,4 The epidemic virulent strains of C difficile,
North American Pulse Field type 1 and PCR ribotype 027
(NAP1/027), are associated with a higher incidence of
disease and more severe and fatal disease.3
The epidemiological data of CDAD are limited in Taiwan.
In addition to our previous prospective study conducted in
2003,5 there was a retrospective study in southern Taiwan.6
The former reported that the incidence of CDAD was 1/
1000 patient-days. The latter found a lower incidence
(0.426/1000 patient-days), but demonstrated an increase
in the quarterly incidence during the study period. The
incidence based on clinical practice might be under-
estimated because the toxin assay was not routinely per-
formed in Taiwan and the sensitivity of the assay varied
widely.7
Due to the low sensitivity of C difficile toxin assay,
current guidelines suggest a two-step method with enzyme
immunoassay (EIA) detection of glutamate dehydrogenase
(GDH) as initial screening followed by a cytotoxic assay or
toxigenic culture.8 However, a cytotoxic assay or toxigenic
culture is either expensive or turnaround takes longer. In
contrast, a combined assay of both toxin and GDH provided
a rapid diagnosis of CDAD with good performance.9
Therefore, we conducted a prospective study as a part
of hospital-wide infection control program and adapted this
combined assay to determine the incidence and clinical
manifestations of CDAD and compared to those of our
previous study.5GDH positive 
Toxin positive 
GDH negative 
Toxin negative 
GDH positive 
Toxin negative 
n = 80 
Clostridium difficile 
associated diarrhea 
n = 8 
Other antibiotic- 
associated diarrhea 
n = 55 
Clostridium difficile
colonization 
n = 17 
Stool culture positive 
n = 4/8 (50%) 
Stool culture positive 
n = 0 (0%) 
Stool culture positive 
n = 10/17 (58.8%) 
Figure 1. Enrollment of patients with antibiotic-associated
diarrhea from June 1, 2010 to October 31, 2010 at National
Taiwan University Hospital.Patients and methods
Hospital setting
National Taiwan University Hospital (NTUH) is a 2200-bed
teaching hospital located in Northern Taiwan. The
hospital-wide hand hygiene program began in April 2004
and is promoted annually.10 According to hospital-wide
infection control surveillance data, high-risk units are
defined either by the number of stool cultures that grew C
difficile or the amount of antimicrobial usage in 2009. A
total of 11 high-risk units were selected for this prospec-
tive study and included 2 infectious disease wards (73
beds), 6 medical intensive care units (ICUs; 62 beds), and 3hemato-oncology wards (82 beds). The study was approved
by the Institutional Review Board of NTUH (NTUH-
201001041R). Inform consent was obtained from patients
enrolled.
Patients
From June 1, 2009 to October 31, 2010, one of the
authors actively surveyed all patients with diarrhea who
were older than 18 years and hospitalized in high-risk
units based on a predefined protocol (Fig. 1). Patients
with diarrhea caused by high osmotic diet, overt gastro-
intestinal bleeding, steatorrhea, laxative use, or docu-
mented parasite-related diarrhea were excluded. Stool
samples were sent to routine laboratory for culture
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pus cell detection. All stool samples were analyzed for
parasite, ameba, and neutral fat to exclude the possibility
of steatorrhea or parasite-related diarrhea. In addition,
active microbial surveillance for stool samples collected
from patients with AAD was performed in the laboratory
of the Center for Infection Control to detect toxin A/B
and GDH using a combined EIA, and the presence of
C difficile by culture.
At these high-risk units, physicians tended to prescribe
antimicrobial therapy empirically and de-escalated later
based on clinical course and microbiological data. If the
response of oral metronidazole was unsatisfied for patients
with C difficile infection or colonization, physicians might
prescribe intravenous metronidazole or oral vancomycin
according to the guidelines.8 Contact isolation and other
infection control measures were conducted immediately
when the status of C difficile infection or colonization was
confirmed.
Data collection
We used a standardized case report form to collect
patient’s demographic data, clinical presentations, labo-
ratory data, microbiological examination results and
treatment outcome. The demographic data included age,
gender, hospital unit (medical ICU, infectious diseases
wards, or hemato-oncology wards), and underlying disease.
Charlson comorbidity index was calculated based on
underlying comorbidities.11 Clinical presentations included
onset date of diarrhea, diarrhea frequency (times/day),
febrile reaction (more than 38.0 C), presence of abdominal
pain, performance status determined by Eastern Coopera-
tive Oncology Group (ECOG),12 antibiotic usage within the
previous 6 weeks, receipt of anticancer chemotherapy and/
or antibiotic within the previous 6 weeks, and use of
proton-pump inhibitors. Laboratory data included blood
leukocyte count, C-reactive protein, biochemistry, stool
pus cell count, and occult blood. Colonization or infection
due to multi-drug resistance Acinetobacter baumannii
(MDRAB), vancomycin-resistance enterococci (VRE), or
Stenotrophomonas maltophilia were collected 30 days
before and after enrollment as surrogate markers of anti-
microbial selection pressure. Antimicrobial therapy and
response (duration of diarrhea), crude mortality, and
attributable mortality were recorded.
Definitions
Diarrhea was defined as more than three loose or watery
stool passages during a 24-hour period. Patients were
considered to have AAD if they had antibiotic usage within 6
weeks prior to the onset of diarrhea and no specific etiology
had been identified as the cause of diarrhea.13 CDAD was
defined as the identification of toxin A or toxin B regardless
of whether C difficile was isolated from stool. Colonization
of C difficile was considered if there was a positive GDH
test and/or positive culture result. Attributable mortality
was defined as persistent diarrhea more than 48 hours
before death and judged by primary care physician and
infectious disease consultant.Microbiological methods
Culture for C difficile
Diarrheal stool sample was inoculated on cycloserine
cefoxitin fructose agar (CCFA).14 CCFA plate was incubated
in an anaerobic chamber at 37C for 48 hours. Growth was
examined with long-wave ultraviolet light (365 nm) for
yellow fluorescence within 1 hour of removal from the
anaerobic atmosphere.15 Colonies suspected to be C difficile
based on microscopic characteristics and specific odor were
confirmed by automatic identification system (anaerobe
identification, VITEK, bioMe´rieux, Durham, NC, USA).
Detection of toxin A/B and GDH antigen
All stool samples were tested by a combined enzyme
immunoassay for toxin A/B and GDH (Techlab C Diff Quik
Chek Complete, Princeton, NJ, USA). Compared to the
toxigenic culture, toxin A/B assay gives 85.9% sensitivity
and 99.5% specificity. The GDH assay provides 97.6% sensi-
tivity and 90.1% specificity.16 The toxin assay used in our
previous study5 (Becton Dickinson ColorPAC Toxin A, Cock-
eysville, MD, USA) had 89% sensitivity and 89% specificity.17
Data analysis and statistical analysis
The number of antimicrobial usage days was determined to
express aggregate antimicrobial usage. One antimicrobial
usage day represents the administration of a single agent
on a given day regardless of the number of doses adminis-
tered or dosage strength.
Statistical analysis was performed by the SPSS for
Windows (version 18.0, SPSS InC, Chicago, IL, USA).
Continuous variables were reported as mean  standard
deviation and compared with one-way ANOVA. Categorical
variables were compared with Chi-square test or Fisher-
exact test. Posthoc analysis was performed by Scheffe
procedure and modified Bonferroni-adjust a for pair-wise
comparisons if the result of ANOVA, Chi-square or Fisher-
exact test was statistically significant. Incidence of CDAD
between the two study periods (2003 vs. 2010) was
compared by Poisson distribution method. A p value <0.05
was considered statistically significant.
Results
During the 5-month study period, a total of 17,685 patient-
days in these 11 high-risk units were surveyed; 152 patients
who received antibiotics and had diarrhea more than three
times per day were screened. Of 80 patients with AAD who
received active microbiological surveillance for CDAD
(Fig. 1), eight had CDAD. Another 17 patients had C difficile
colonization. Among 72 patients who did not receive active
microbial surveillance, stool samples of 26 patients were
sent for C difficile isolation and all were negative. In 80
patients with AAD who received active microbial surveil-
lance, compared with stool culture only, a combined toxin
and GDH assay identified 11 more patients with C difficile
colonization or infection (total 25 vs. 14 patients).
290 Y.-C. Lee et al.Thus, the prevalence of CDAD was 10.0% (8 out of 80) of
overall AAD. The overall incidence of AAD was 4.5/1000
patient-days (80 out of 17,685), and that of CDAD was 0.45/
1000 patient-days (8 out of 17,685). The incidence was
highest in medical ICUs (7.9/1000 patient-days, 4 out of
5051), followed by hemato-oncology wards (0.42/1000
patient-days, 3 out of 7213) and infectious diseases wards
(0.18/1000 patient-days, 1 out of 5421).
The demographic and clinical characteristics of patients
with CDAD, C difficile colonization and other AAD are shown
in Tables 1 and 2, respectively. There was no difference in
age, gender, study unit, Charlson comorbidity, underlying
diseases, duration and frequency of diarrhea, febrile
illness, abdominal pain, ECOG score, hospitalization, and
receipt of chemotherapy or antibiotic 6 months prior to
admission, and proton pump inhibitor use. Length of
hospital stay either before or after enrollment was longer in
patients with CDAD than in other two groups, although
statistically insignificant. A stool pus cell count of 3 per high
power field or more was more frequent in patients with
CDAD than the other two groups (37.5%, 17.6%, and 5.5%,
p Z 0.018). Only half of the patients with CDAD or
C difficile colonization had a positive stool culture for
C difficile. There was no difference in prevalence of colo-
nization or infection due to MDRAB, VRE, or S maltophilia
among the three groups.Table 1 Baseline characteristics of patients with Clostridum di
antibiotic-associated diarrhea
Baseline characteristics C difficile-asso
diarrhea (n Z
Age (years), mean  SD 63.88  25.18
Gender
Male, n (%) 5 (62.5)
Female, n (%) 3 (37.5)
Study site
Infectious disease ward, n (%) 1 (12.5)
Hemato-oncology ward, n (%) 3 (37.5)
Medical intensive care unit, n (%) 4 (50.0)
Charlson comorbidity index, mean  SD 3.63  2.60
Congestive heart failure, n (%) 1 (12.5)
Peripheral arterial occlusive Disease, n (%) 0 (0.0)
Chronic obstructive pulmonary Disease, n (%) 1 (12.5)
Peptic ulcer disease, n (%) 1 (12.5)
Cirrhosis of liver, n (%) 0 (0.0)
Chronic kidney disease, n (%) 2 (25.0)
Connective tissue disease, n (%) 0 (0.0)
Diabetes mellitus, n (%) 3 (37.5)
Cerebral vascular accident, n (%) 0 (0.0)
Solid organ malignancy, n (%) 2 (25.0)
Leukemia, n (%) 3 (37.5)
Lymphoma, n (%) 0 (0.0)
Acquired immunodeficiency syndrome, n (%) 0 (0.0)
Solid organ transplant, n (%) 0 (0.0)
Hematopoietic stem cell transplant, n (%) 1 (12.5)
Immunosuppressants use, n (%) 4 (50.0)
SD Z standard deviation.Table 3 shows the proportion of patients receiving indi-
cated intravenous and oral antimicrobial agents within 6
weeks prior to enrollment and the antimicrobial usage days
per patient in each group. Occurrence of CDAD was asso-
ciated with more antimicrobial usage days of beta-
lactamase stable penicillins (p Z 0.046) and anaerobe-
active agents (p Z 0.029). In addition, CDAD patients
were more likely to have prior use of either intravenous or
oral metronidazole (p Z 0.042).
Table 4 compares the treatment regimen, response and
clinical outcomeamong the three groups. PatientswithCDAD
and C difficile colonization received treatment more than
those with AAD (p < 0.001). All 8 CDAD patients and 16 of 17
patient with C difficile colonization received either metro-
nidazole or vancomycin therapy. However, only 36.3% of the
other AAD patientswere treated. Among 43 patients treated,
27 patients were treated with oral metronidazole, 12 with
intravenous metronidazole, two with oral vancomycin and
one with combination therapy (intravenous metronidazole
with oral vancomycin).Oral vancomycinwasmore frequently
prescribed in patients with CDAD (p Z 0.009). Treatment
duration was longest in patients with patients with CDAD
(p < 0.001). Regarding clinical outcome, there was no
mortality attributable to C difficile infection identified.
Hospital mortality due to any cause was lower in patients
with other antibiotic associated diarrhea (pZ 0.042).fficile-associated diarrhea, C difficile colonization, and other
ciated
8)
C difficile
colonization
(n Z 17)
Other antibiotic-
associated diarrhea
(n Z 55)
p value
65.59  17.34 62.85  18.99 0.88
10 (58.8) 30 (54.5) 0.89
7 (41.2) 25 (45.5)
3 (17.6) 13 (23.6) 0.71
6 (35.3) 15 (27.3) 0.73
8 (47.1) 27 (49.1) 0.99
4.47  4.43 3.44  3.25 0.56
4 (23.5) 3 (5.5) 0.09
1 (5.9) 1 (1.8) 0.58
2 (11.8) 3 (5.5) 0.59
1 (5.9) 8 (14.5) 0.64
1 (5.9) 0 (0.0) 0.15
4 (23.5) 5 (9.1) 0.20
3 (17.6) 5 (9.1) 0.36
5 (29.4) 13 (23.6) 0.67
4 (23.5) 12 (21.8) 0.32
3 (17.6) 10 (18.2) 0.89
5 (29.4) 9 (16.4) 0.26
3 (17.6) 8 (14.5) 0.47
0 (0.0) 2 (3.6) 0.63
1 (5.9) 1 (1.8) 0.58
3 (17.6) 8 (10.9) 0.76
12 (70.6) 22 (40.0) 0.08
Table 2 Clinical manifestations of patients with Clostridium difficile-associated diarrhea, C difficile colonizaiton and other
antibiotic-associated diarrhea
Clinical manifestations C difficile-
associated
diarrhea
(n Z 8)
C difficile
colonization
(n Z 17)
Other antibiotic-
associated diarrhea
(n Z 55)
p value
Diarrhea
Duration, days (mean  SD) 3.50  2.33 2.06  1.30 3.45  3.30 0.22
Frequency, times per day (mean  SD) 6.25  3.58 5.35  2.26 5.53  2.89 0.75
Fever (body temperature 38.0C), n (%) 2 (25.0) 5 (29.4) 26 (47.3) 0.26
Abdominal pain, n (%) 3 (37.5) 1 (5.9) 12 (21.8) 0.15
ECOG score  3, n (%) 6 (75.0) 10 (58.9) 41 (74.5) 0.93
Hospitalization within 6 months prior to
admission, n (%)
5 (62.5) 11 (64.7) 26 (47.3) 0.38
Receipt of chemotherapy within 6 months prior to
diarrhea, n (%)
4 (50.0) 9 (52.9) 16 (29.1) 0.14
Receipt of antibiotic within 6 months prior to
diarrhea, n (%)
7 (87.5) 12 (70.6) 38 (69.1) 0.56
Proton pump inhibitor use, n (%) 5 (62.5) 10 (58.8) 32 (58.2) 0.97
Length of hospital stay before enrollment (days),
mean  SD
40.00  32.30 20.18  17.88 21.58  22.57 0.09
Length of hospital stay after enrollment (days),
mean  SD
46.13  29.47 25.29  20.72 34.65  30.16 0.22
Laboratory data
White blood count (x 109/L),mean  SD 8.145  7.620 10.914  10.527 9.954  10.937 0.83
Neutropenia
(ANCc < 500  106/L), n (%) 2 (25.0) 3 (17.6) 7 (12.7) 0.62
Hemoglobin (g/L), mean  SD 96.0  9.8 99.4  16.1 97.3  15.5 0.85
Platelet (109/L), mean  SD 126.38  126.24 149.88  99.58 155.41  137.86 0.84
C-reactive protein (mg/L), mean  SD 61.6  50.1 73.2  76.4 86.5  96.3 0.70
Albumin (g/L), mean  SD 27.8  6.6 33.1  7.5 29.3  6.1 0.07
Creatinine (mg/L), mean  SD 13.6  13.3 18.3  20.1 16.2  16.8 0.81
Stool occult blood  3, n (%) 2 (25.0) 4 (23.5) 17 (30.9) 0.24
Stool pus cell  3e5/HPF, n (%) 3 (37.5) 3 (17.6) 3 (5.5) 0.018
Microbiology data, n (%)
Stool culture positive for Clostridium difficile,
n (%)
4 (50.0) 10 (58.8) 0 (0.0) <0.001
30 days before enrollment
MDRAB e colonization/infection, n (%) 1 (12.5) 2 (11.8) 7 (12.7) 0.99
VRE f colonization/infection, n (%) 2 (25.0) 1 (5.9) 10 (18.2) 0.38
Stenotrophomonas maltophilia colonization/
infection, n (%)
3 (37.5) 4 (23.5) 8 (14.6) 0.25
30 days after enrollment
MDRAB colonization/infection, n (%) 1 (12.5) 1 (5.9) 7 (12.7) 0.73
VRE colonization/infection, n (%) 1 (12.5) 2 (11.8) 4 (7.3) 0.78
Stenotrophomonas maltophilia colonization/
infection, n (%)
2 (25.0) 5 (29.4) 12 (21.8) 0.81
ANC Z Absolute neutrophil count; ECOG score Z Eastern Cooperation of Oncology Group score; HPF Z high power field;
MDRAB Z multidrug resistance Acinetobacter baumannii defined as resistance to three or more classes of antimicrobials, including
ampicillin-sulbactam, antipseudomonal cephalosporins, anti-pseudomonal carbapenems, aminoglycosides, and fluoroquinolones;
SD Z standard deviation; VRE Z vancomycin-resistant enterococci.
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study conducted in 20035 showed that the incidence of AAD
(4.5/1000 vs. 8.0/1000 patient-days, p < 0.001) and that of
CDAD (0.45/1000 vs. 1.0/1000 patient-days, p < 0.001) was
lower in this study. As the previous study did not include
hemato-oncologywards, we repeated data analysis for thosedata collected from medical ICUs and infectious diseases
wards. The conclusion remained the same (AAD incidence
5.3/1000 vs. 8.0/1000 patient-days, CDAD incidence, 0.48/
1000 vs. 1.0/1000 patient-days, p < 0.001 for both). There
was no difference of the prevalence of CDAD in AAD between
2 study periods (10.0% vs. 12.5%, pZ 0.87).
Table 3 Antimicrobial usage within 6 weeks prior to diarrhea in patients with Clostridium difficile-associated diarrhea,
C difficile colonization and other antibiotic-associated diarrhea
Antimicrobial usagea C difficile-associated
diarrhea (n Z 8)
C difficile colonization
(n Z 17)
Other antibiotic-
associated diarrhea
(n Z 55)
p value
Betalactamase-stable penicillinb 2 (25.0) 9 (52.94) 27 (49.09) 0.39
8.5  2.12 4.9  4.49 3.3  2.42 0.046
Cephalosporins 7 (87.50) 14 (82.35) 45 (81.82) 0.92
6.4  7.04 7.7  6.53 6.9  5.33 0.86
1st and 2nd generation d 3 (17.65) 6 (10.91) 0.42
2.0  1.00 3.0  2.10 0.47
3rd and 4th generation 7 (87.5) 13 (76.47) 44 (80.0) 0.81
6.4  7.04 7.8  6.53 6.7  5.28 0.80
Fluoroquinolonesc 3 (37.5) 5 (29.41) 21 (38.18) 0.80
4.7  5.51 3.8  3.03 8.1  7.51 0.38
Carbapenemsd 5 (62.5) 9 (52.94) 22 (40.0) 0.37
12.8  5.85 6.11  4.08 9.6  6.28 0.12
Glycopeptidese 4 (50.0) 5 (29.41) 20 (36.36) 0.61
4.3  4.57 5.6  8.11 9.0  8.18 0.44
Metronidazole 4 (50.0) 1 (5.88) 12 (21.82) 0.042
8.5  3.87 1.0 4.8  4.18 0.23
Narrow spectrum antibioticf 4 (50.0) 10 (58.82) 34 (61.82) 0.81
5.5  4.04 7.9  10.09 8.0  7.27 0.83
Broad spectrum antibioticg 8 (100.0) 16 (94.12) 52 (94.55) 0.79
16.6  10.93 12.29.138 13.5  11.05 0.63
Anaerobic-active antibiotich 7 (87.5) 15 (88.24) 45 (81.82) 0.78
15.9  9.72 6.9  3.83 9.5  7.61 0.029
Anti-fungal agentsi 5 (62.5) 9 (52.94) 29 (52.73) 0.87
12.2  12.11 18.3  12.40 16.0  11.303 0.64
a Data are shown in number (%) and antimicrobial usage days (mean  standard deviation).
b Betalactamase-stable penicillins including amoxicillin-clavulanate, ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin-
tazobactam.
c Fluoroquinolones including levofloxacin, moxifloxacin, ciprofloxacin.
d Carbapenems including meropenem, imipenem, ertapenem.
e Glycopeptides including vancomycin, teicoplanin.
f Narrow spectrum antibiotic including penicillin, ampicillin, amoxicillin, amoxicillin-clavulanate, ampicillin-sulbactam, clindamycin,
cephalexin, cefazolin, cefmetazole, cefuroxime, vancomycin, teicoplanin, daptomycin, linezolid.
g Broad spectrum antibiotic including piperacillin-tazobactam, ticarcillin-clavulanate, ceftriaxone, cefotaxime, ceftazidime, flo-
moxef, cefepime, cefpirome, carbapenems, fluoroquinolones, tigecycline, aminoglycosides, aztreonam.
h Anaerobe-active antibiotic including ampicillin-sulbactam, amoxicillin-clavulanate, clindamycin, piperacillin-tazobactam, ticarcil-
lin-clavulanate, cefmetazole,flomoxef, metronidazole, moxifloxacin, carbapenems, tigecycline.
i Anti-fungal agents: fluconazole, itraconazole, voriconazole, nystatin, amphotericin B, micafungin, caspofungin, anidulafungin.
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were compared between two study periods (Table 5). The
current study population was associated with a lower rate
of hospitalization within 6 months (p Z 0.001) and higher
portion of chemotherapy receipt within 6 months
(p Z 0.035). There was no difference in older age (65
years old), Charlson comorbidity index, or proportion of
antibiotic use 6 weeks prior to diarrhea.Discussion
This 5-month, prospective, active surveillance study of
patients with AAD in high-risk units at a large teaching
hospital demonstrated a lower incidence of AAD and CDAD
than that of our previous study in 2003.5 This result wasdifferent from an increasing incidence in Southern Taiwan
and in Oregon, USA.6,19 The result was concordant with the
decreasing trends of MDRAB and methicillin-resistant
Staphylococcus aureus following a hospital-wide hand
hygiene promotion program in this hospital.10 Regarding
antimicrobial selection pressure, three studies have
described the decreasing incidence of CDAD as related to
antibiotic restriction policies.20e22 Two studies showed that
the incidence of CDAD was associated with increasing
antibiotic consumption or some kind of antibiotic use, but
both failed to support the association of alcohol-based hand
rub usage and CDAD.23,24 However, there was no difference
on proportion of antibiotic use between the two study
periods and no specific antibiotic stewardship program
promoted during 2003e2010 at this hospital. Therefore, the
impact of hand hygiene promotion and other infection
Table 4 Treatment response and outcome of patients with Clostridium difficile-associated diarrhea, C difficile colonization
and other antibiotic-associated diarrhea
Parameter C difficile-associated
diarrhea (n Z 8)
C difficile colonization
(n Z 17)
Other antibiotic-
associated diarrhea
(n Z 55)
p value
Antimicrobial therapy, n (%) 8/8 (100) 16/17 (94.1) 20/55 (36.3) <0.001
Oral metronidazole, n (%) 5/8 (62.5) 14/16 (87.5) 10/20 (50.0) 0.060
Intravenous metronidazole,
n (%)
2/8 (25.0) 2/16 (12.5) 10/20 (50.0) 0.051
Oral vancomycin, n (%) 2/8 (25.0) 0/16 (0.0) 0/20 (0.0) 0.009
Duration (days), mean  SD 16.25  13.33 8.06  4.14 4.80  1.82 <0.001
Therapeutic response
Diarrhea duration after
treatment
7.13  11.59 6.00  6.55 3.50  5.53 0.41
Outcome, n (%)
7-day mortality 0 (0.0) 0 (0.0) 3 (5.5) 0.49
14-day mortality 0 (0.0) 2 (11.8) 4 (7.3) 0.58
30-day mortality 2 (25.0) 6 (40.0) 8 (16.0) 0.14
In-hospital mortality 4 (50.0) 9 (52.9) 13 (23.6) 0.042
SD Z standard deviation.
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current study warrants further elucidation.
Furthermore, neither attributable mortality nor
morbidity of CDAD was identified in this study. The attrib-
utable mortality ranged from 5.7% to 6.9% in previous
studies, which were associated with epidemic hypervirulent
NAP1/027 strain of C difficile.3,25 The epidemic hyperviru-
lent strain was associated with a higher incidence of
disease and fatal disease.3 However, the NAP1/027 strain
has not been identified in northern and southern Taiwan,26
which might contribute to the lower attributable mortality
in the current study.
We established and confirmed a useful diagnostic
protocol coupling the use of a sensitive combined antigenTable 5 Comparisons of risk factors of Clostridium difficile-a
studies5 at National Taiwan University Hospital
Characteristic Hsu et al.5 2003, (n Z
Age (years), mean  SD 64.3  17.7
Age (years) 65 years (%) 28 (58.3)
Charlson comorbidity index,
mean  SD
4.00  3.69
Hospitalization within 6 months
prior to admission, n (%)
39 (81.2)
Chemotherapy within 6 months
prior to diarrhea, n (%)
10 (20.8)
Prior antibiotics use within 6 weeks prior to diarrhea, n (%)
Penicillins 23 (47.9)
Cephalosporins 37 (77.1)
Carbapenems 16 (33.3)
Fluoroquinolones 19 (39.6)
Glycopeptides 21 (43.8)
Metronidazoles 16 (33.3)
SD Z standard deviation.assay. After exclusion of other known etiologies, this
flowchart identified one patient with CDAD per 10 patients
with AAD and did not miss any patient with C difficile
colonization or infection. A stool pus cell count of 3 per
high power field or more was noted in only 37.5% of CDAD
cases. This finding was concordant with a previous report
that, compared with toxin assay, stool pus cell count gives
a 30% sensitivity and 74.9% specificity.27 Thus, stool pus
cell count is not a good screening test for CDAD. This study
utilizes combination of toxin and GDH assay to detect
patients with CDAD or C difficile colonization. Only half of
them had a positive stool culture for C difficile, which may
result from difficulty in its isolation.28 Thus, current
guidelines suggest the use of GDH assay as an initialssociated diarrhea in patients enrolled in this and previous
48) Current study 2010, (n Z 80) p value
63.5  19.1 0.82
42 (52.5) 0.521
3.68  3.46 0.62
42 (52.5) 0.001
31 (38.8) 0.035
39 (48.8) 0.93
66 (82.5) 0.45
36 (45.0) 0.19
29 (36.2) 0.71
29 (36.2) 0.40
17 (21.2) 0.13
294 Y.-C. Lee et al.screening test followed by toxin assay or toxigenic
culture.8
There was an unexpected finding that prior use of
metronidazole was more common in CDAD patients than
other two groups (p Z 0.042). Due to the limitation of
routine diagnostic methods, physicians tended to use
metronidazole empirically for high-risk patients with AAD.
Treatment without the documentation of CDAD may be
incomplete or inadequate. Therefore, CDAD patients in the
current study tended to have more oral vancomycin as
second line therapy.
In conclusion, this study identified a lower incidence of
CDAD than that in 2003 in a teaching hospital in northern
Taiwan and the absence of attributable mortality following
a hospital-wide hand hygiene program. This study
confirmed our concern that culture methods identified only
half of patients with C difficile colonization or infection.
Cross transmission and environmental contamination from
these undetected patients might at least in part contribute
to the rapid spread of C difficle worldwide.
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